Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.17
DEPO's Cash to Debt is ranked lower than
89% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. DEPO: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
DEPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 11.77 Max: No Debt
Current: 0.17
Equity to Asset 0.24
DEPO's Equity to Asset is ranked lower than
92% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. DEPO: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
DEPO' s Equity to Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.36 Max: 0.97
Current: 0.24
-2.63
0.97
F-Score: 3
Z-Score: 1.00
M-Score: -2.91
WACC vs ROIC
19.79%
-1.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.11
DEPO's Operating margin (%) is ranked lower than
78% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.87 vs. DEPO: -4.11 )
Ranked among companies with meaningful Operating margin (%) only.
DEPO' s Operating margin (%) Range Over the Past 10 Years
Min: -601.86  Med: -14.47 Max: 72.49
Current: -4.11
-601.86
72.49
Net-margin (%) -16.89
DEPO's Net-margin (%) is ranked lower than
82% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. DEPO: -16.89 )
Ranked among companies with meaningful Net-margin (%) only.
DEPO' s Net-margin (%) Range Over the Past 10 Years
Min: -555.44  Med: -13.99 Max: 75.05
Current: -16.89
-555.44
75.05
ROE (%) -23.10
DEPO's ROE (%) is ranked lower than
81% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.03 vs. DEPO: -23.10 )
Ranked among companies with meaningful ROE (%) only.
DEPO' s ROE (%) Range Over the Past 10 Years
Min: -333.8  Med: 20.07 Max: 532.43
Current: -23.1
-333.8
532.43
ROA (%) -5.57
DEPO's ROA (%) is ranked lower than
76% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. DEPO: -5.57 )
Ranked among companies with meaningful ROA (%) only.
DEPO' s ROA (%) Range Over the Past 10 Years
Min: -66.64  Med: -6.53 Max: 73.87
Current: -5.57
-66.64
73.87
ROC (Joel Greenblatt) (%) -148.98
DEPO's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.38 vs. DEPO: -148.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DEPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2282.52  Med: -260.35 Max: 8060.52
Current: -148.98
-2282.52
8060.52
Revenue Growth (3Y)(%) 35.40
DEPO's Revenue Growth (3Y)(%) is ranked higher than
92% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. DEPO: 35.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DEPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.4  Med: 25.5 Max: 517.8
Current: 35.4
-74.4
517.8
EBITDA Growth (3Y)(%) 43.20
DEPO's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. DEPO: 43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DEPO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: 6.7 Max: 84.1
Current: 43.2
-55.5
84.1
EPS Growth (3Y)(%) 17.60
DEPO's EPS Growth (3Y)(%) is ranked higher than
67% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. DEPO: 17.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DEPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.5  Med: -6.3 Max: 180.8
Current: 17.6
-59.5
180.8
» DEPO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DEPO Guru Trades in Q3 2015

Jim Simons 104,146 sh (New)
Paul Tudor Jones 40,800 sh (+56.32%)
Joel Greenblatt 264,236 sh (-68.63%)
» More
Q4 2015

DEPO Guru Trades in Q4 2015

John Hussman 200,000 sh (New)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 30,900 sh (-24.26%)
» More
Q1 2016

DEPO Guru Trades in Q1 2016

Steven Cohen 1,866,629 sh (New)
John Hussman 200,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

DEPO Guru Trades in Q2 2016

Joel Greenblatt 47,318 sh (New)
Steven Cohen Sold Out
John Hussman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:LCI, NAS:CPXX, NAS:SUPN, NAS:EGRX, NAS:PCRX, NAS:AMPH, OTCPK:KHTRF, NAS:MNTA, NAS:SGYP, NAS:HRTX, NAS:INNL, NAS:SGNT, OTCPK:LPCUF, OTCPK:EVTCY, NAS:IPXL, NAS:ACET, NAS:SCLN, NAS:SCMP, NAS:LBIO, NAS:FLXN » details
Traded in other countries:DPO.Germany,
DepoMed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.

Ratios

vs
industry
vs
history
Forward P/E 16.00
DEPO's Forward P/E is ranked higher than
60% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.89 vs. DEPO: 16.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 21.86
DEPO's Price/Owner Earnings (ttm) is ranked higher than
70% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.58 vs. DEPO: 21.86 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DEPO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.68  Med: 7.5 Max: 212
Current: 21.86
2.68
212
P/B 4.01
DEPO's P/B is ranked lower than
63% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. DEPO: 4.01 )
Ranked among companies with meaningful P/B only.
DEPO' s P/B Range Over the Past 10 Years
Min: 2  Med: 4.17 Max: 22.64
Current: 4.01
2
22.64
P/S 2.70
DEPO's P/S is ranked higher than
51% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. DEPO: 2.70 )
Ranked among companies with meaningful P/S only.
DEPO' s P/S Range Over the Past 10 Years
Min: 1.38  Med: 3.45 Max: 210.94
Current: 2.7
1.38
210.94
PFCF 10.21
DEPO's PFCF is ranked higher than
86% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.70 vs. DEPO: 10.21 )
Ranked among companies with meaningful PFCF only.
DEPO' s PFCF Range Over the Past 10 Years
Min: 2.31  Med: 9.15 Max: 265.87
Current: 10.21
2.31
265.87
POCF 9.95
DEPO's POCF is ranked higher than
76% of the 248 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. DEPO: 9.95 )
Ranked among companies with meaningful POCF only.
DEPO' s POCF Range Over the Past 10 Years
Min: 2.28  Med: 9.19 Max: 251.36
Current: 9.95
2.28
251.36
EV-to-EBITDA 20.42
DEPO's EV-to-EBITDA is ranked lower than
58% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.57 vs. DEPO: 20.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: -0.3 Max: 124.5
Current: 20.42
-582.9
124.5
Shiller P/E 123.08
DEPO's Shiller P/E is ranked lower than
85% of the 154 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.01 vs. DEPO: 123.08 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s Shiller P/E Range Over the Past 10 Years
Min: 75.75  Med: 116.14 Max: 387.25
Current: 123.08
75.75
387.25
Current Ratio 1.06
DEPO's Current Ratio is ranked lower than
86% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DEPO: 1.06 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3 Max: 56
Current: 1.06
0.57
56
Quick Ratio 1.01
DEPO's Quick Ratio is ranked lower than
75% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. DEPO: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.94 Max: 56
Current: 1.01
0.57
56
Days Inventory 45.20
DEPO's Days Inventory is ranked higher than
86% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. DEPO: 45.20 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 45.2  Med: 226.72 Max: 613.73
Current: 45.2
45.2
613.73
Days Sales Outstanding 66.31
DEPO's Days Sales Outstanding is ranked higher than
59% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.29 vs. DEPO: 66.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 347.08
Current: 66.31
12.13
347.08
Days Payable 47.76
DEPO's Days Payable is ranked lower than
70% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.16 vs. DEPO: 47.76 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 142.64 Max: 1113.92
Current: 47.76
30.8
1113.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.20
DEPO's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. DEPO: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DEPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.9  Med: -9.45 Max: -2.2
Current: -2.2
-58.9
-2.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.20
DEPO's Price/Projected FCF is ranked higher than
54% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. DEPO: 2.20 )
Ranked among companies with meaningful Price/Projected FCF only.
DEPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.18  Med: 2.23 Max: 335
Current: 2.2
1.18
335
Price/Median PS Value 0.78
DEPO's Price/Median PS Value is ranked higher than
82% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. DEPO: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 3.56 Max: 394
Current: 0.78
0.44
394
Earnings Yield (Greenblatt) (%) -1.29
DEPO's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DEPO: -1.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DEPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.31  Med: 17.25 Max: 266.4
Current: -1.29
-1.31
266.4

More Statistics

Revenue (TTM) (Mil) $437.5
EPS (TTM) $ -1.22
Beta1.35
Short Percentage of Float21.56%
52-Week Range $12.25 - 29.44
Shares Outstanding (Mil)61.37

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 482 585 675
EPS ($) 1.21 1.64 2.13
EPS w/o NRI ($) 1.21 1.64 2.13
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
ETF’s with exposure to Depomed, Inc. : August 29, 2016 Aug 29 2016
Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : August 26, 2016 Aug 26 2016
Infoblox, Depomed, Insperity: Inside Starboard Value’s 5 Biggest Moves of Q2 Aug 17 2016
Why a hedge fund wants this East Bay drug company to run like Olive Garden Aug 16 2016
Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
DEPOMED INC Financials Aug 11 2016
5 stocks to watch Aug 10 2016
ETF’s with exposure to Depomed, Inc. : August 8, 2016 Aug 08 2016
Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : August 5, 2016 Aug 05 2016
Edited Transcript of DEPO earnings conference call or presentation 3-Aug-16 8:30pm GMT Aug 04 2016
Depomed reports 2Q loss Aug 03 2016
Depomed reports 2Q loss Aug 03 2016
Depomed Inc Earnings Call scheduled for 4:30 pm ET today Aug 03 2016
Depomed Reports Second Quarter 2016 Financial Results Aug 03 2016
DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 03 2016
Depomed Reports Second Quarter 2016 Financial Results Aug 03 2016
Q2 2016 Depomed Inc Earnings Release - After Market Close Aug 03 2016
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 Jul 27 2016
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 Jul 27 2016
DepoMed downgraded by Piper Jaffray Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)